Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Figures & data

Figure 1. The Kaplan–Meier plot of drug survival in patients with moderate-to-severe psoriasis from the DERMBIO registry treated with biologics (2).

Figure 2. Comparison of TNF neutralization activity of SB4 and etanercept reference product (40 lots of EU-sourced product and 40 lots of US-sourced product), with the dotted line indicating the similarity range based on results of etanercept reference product obtained from the EU (35).

Figure 3. Psoriasis Area and Severity Index (PASI) scores during 6 months of treatment with etanercept biosimilar SB4 in patients from the PsoBiosimilars registry switched from reference etanercept and in etanercept-naive patients (45). *p<.05 vs. baseline.

Figure 4. The Kaplan–Meier plot of drug survival in patients with moderate-to-severe psoriasis in the DERMBIO registry treated with reference etanercept or switched from reference etanercept to etanercept biosimilar SB4 (2).

Table 1. Biosimilars with EMA approval for the treatment of moderate-to-severe psoriasis (current October 2018) (1, 58, 59).

Reference product INN (brand name)	Biosimilar product
	Code name	Brand name	Drug company	Clinical studies conducted for approval	Approval year
Infliximab (Remicade)	CT-P13	Inflectra/Remsima	Celltrion	AS, RA	2013
	SB2	Flixabi	Samsung Bioepis	RA	2016
	PF-06438179/GP111	Zessly	Sanodoz	RA	2018
Etanercept (Enbrel)	SB4	Benepali	Samsung Bioepis	RA	2016
	GP2015	Erelzi	Sandoz	PsO	2017
Adalimumab (Humira)	ABP501	Amgevita/Solymbic	Amgen	PSO, RA	2017
	SB5	Imraldi	Samsung Bioepis	RA	2017
	BI 695501	Cyltezo	Boehringer Ingelheim	RA	2017
	GP2017	Halimatoz/Hefiya/Hyrimoz	Sandoz	PsO	2018
	FKB327	Hulio	Fujifilm Kyowa Kirin Biologics	RA	2018

AS: ankylosing spondylitis; EMA: European Medicines Agency; INN: International Nonproprietary Name; PsO: psoriasis; RA: rheumatoid arthritis.

Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519.

 PubMed Web of Science ®Google Scholar

Cho IH, Lee N, Song D, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. mAbs. 2016;8:1136–1155.

 PubMed Web of Science ®Google Scholar

Gisondi P, Bianchi L, Calzavara-Pinton P, et al. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2019;180(2):409–410.

 PubMed Web of Science ®Google Scholar

Carrascosa J-M, Jacobs I, Petersel D, et al. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb). 2018;8:173–194.

 PubMed Web of Science ®Google Scholar

Generics Biosimilars Initiative. Adalimumab and trastuzumab biosimilars gain EC approval; 2018 [cited 2018 Dec]. Available from: http://www.gabionline.net/Biosimilars/News/Adalimumab-and-trastuzumab-biosimilars-gain-EC-approval

 Google Scholar

Generics Biosimilars Initiative. EC approval for adalimumab and pegfilgrastim biosimilars Hulio and Udenyca; 2018 [cited 2018 Dec]. Available from: http://www.gabionline.net/Biosimilars/News/EC-approval-for-adalimumab-and-pegfilgrastim-biosimilars-Hulio-and-Udenyca

 Google Scholar